CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) received a strong endorsement from leading cancer specialists for its Parsortix platform, as the company confirmed it is preparing to raise around £6 million to support its growth plans.
The med-tech group, which changed its name from ANGLE last week, said an international panel of experts has identified Parsortix as one of the most promising next-generation tools for advancing cancer diagnosis and treatment.
A consensus paper, published in the European Journal of Cancer, highlighted the growing clinical importance of analysing circulating tumour cells, whole cancer cells that break away from tumours and circulate in the bloodstream, to monitor disease and guide treatment.
Based on contributions from 32 oncologists and research leaders, the paper found that CTCs provide biological insights not captured by circulating tumour DNA, another blood-based testing method already used in oncology.
Some 90% of respondents said they expect CTC testing to become part of routine hospital practice within the next five years, particularly in managing advanced cancers.
Notably, 40% of those surveyed identified CelLBxHealth’s Parsortix system as the leading technology in the field.
Chief executive Peter Collins said: “This independent expert consensus further demonstrates the important role that CTCs stand to play in cancer treatment into the future, and identifies the Parsortix platform as a go-to platform in the space.”
In the update, CelLBxHealth said it has a cash runway into early 2026 and has started talks with investors ahead of the planned fundraising, which will include an institutional placing and retail offer.
The company expects to confirm the details by early December.